nxc736
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 10, 2021 (NCT05079425)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
S1PR2 inhibitor
- Sphingosine 1-phosphate receptor 1INHIBITOR
S1PR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06104839 | Phase 2 | Apr 1, 2024 | — |
| NCT05079425 | Phase 1 | Sep 10, 2021 | NEXTGEN Bioscience, Seoul National University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NEXTGEN Bioscience | For profit | 1 | 1 | 1 | 2021 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1